Phase
Condition
Insomnia
Nocturia
Treatment
Health Education Program
Integrated Behavioral Therapy Program
Clinical Study ID
Ages > 60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥ 60 years
Average of ≥ 2 episodes per night of nocturia on the International Consultation onIncontinence Questionnaire-Overactive Bladder Module (ICIQ-OAB) questionnaire
Insomnia Severity Index > 7
Able to attend weekly study visits
Exclusion
Exclusion Criteria:
Prior cognitive behavioral therapy for insomnia
Presence of bipolar disorder
Significant cognitive impairment as measured by a score < 20 on the Mini-MentalState Exam
Sleep disturbance better explained by another sleep disorder such as restless legssyndrome, narcolepsy, insufficient sleep syndrome, or circadian rhythm sleep-wakedisorders
Untreated sleep-disordered breathing (respiratory event index ≥ 15 plus • EpworthSleepiness Scale > 10 or respiratory event index > 30. Note that participants withtreated sleep-disordered breathing will not be excluded)
Current urinary tract infection or hematuria
Unstable doses or recent changes in bladder medication
New or recently discontinued insomnia medication within past month
Previous or current intensive behavioral therapy for insomnia or urinary symptoms,
Unstable health conditions expected to result in death or hospitalization within 3months, as assessed by overall study PIs or Site PI.
Unstable medical conditions that could contribute to nocturia or insomnia such aspoorly controlled heart failure as evidenced on physical examination, poorlycontrolled diabetes mellitus with either hemoglobin A1c of ≥ 9.0, or chronic kidneydisease (stage 4 or 5) or a potential to initiate dialysis in 3 months
Unstable psychiatric conditions (e.g., psychosis, active alcohol/substance abusebased on history and medical records)
Unstable housing situation
Evidence of significant urinary retention as measured by a residual bladder volumeof ≥ 200 mL by bladder ultrasound with 15 minutes of voiding
Genitourinary cancer undergoing active treatment
Pelvic or colon surgery within 6 months of enrollment or onabotulinum toxin therapyfor urinary symptoms within 6 months of enrollment
Study Design
Study Description
Connect with a study center
VA Greater Los Angeles Healthcare System
Los Angeles, California 91343
United StatesSite Not Available
VA Greater Los Angeles Healthcare System
Los Angeles 5368361, California 5332921 91343
United StatesActive - Recruiting
Atlanta VAHCS
Atlanta, Georgia 30033
United StatesSite Not Available
Atlanta VAHCS
Atlanta 4180439, Georgia 4197000 30033
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.